Compare Okta, Inc. (OKTA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs TG Therapeutics Inc — how do they compare? Okta, Inc. trades at $136.51 (market cap $24.63B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Okta, Inc. is far larger — about 3× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| OKTA | TGTX | |
|---|---|---|
Market Cap | $24.63B | $8.26B |
Sector | Technology | Health |
52-Week High | $154.62 | $59.06 |
52-Week Low | $62.93 | $26.39 |
Enterprise Value | $22.45B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $141.63, down 5.17% in the last session amid broader market volatility. The stock shows strong fundamental improvement with revenue growing to $2.61B in 2025 and achieving positive net income of $28M after years of losses. Technical indicators suggest a bullish trend with strong moving average signals, while oscillators remain neutral. Recent analyst coverage remains overwhelmingly positive with 37 buy ratings versus 2 sell ratings.
The outlook remains constructive given OKTA's position in the growing cybersecurity sector and improving profitability. Key risks include high valuation multiples (P/E of 107.54) and competitive pressures. The consensus price target of $127.96 suggests potential downside from current levels, though the high target of $175.00 indicates significant upside potential if execution continues.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
